BAX INVESTOR ALERT: Baxter International Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump, which reportedly has systemic defects that pose serious risks to patients [3][4]. Summary by Sections Class Action Lawsuit Details - The lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the class action [1]. Allegations Against Baxter - Baxter allegedly made false or misleading statements and failed to disclose significant issues with the Novum IQ LVP, including systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - The company was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues were deemed inadequate, as design flaws persisted, continuing to harm patients [3]. Impact on Stock Price - Following Baxter's announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, the company's stock price fell by more than 22% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].